News Quantified

SMMT – summit therapeutics inc. (US:NASDAQ)

Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $7.00 price target on the stock.

5/1

07:12 am

smmt

High

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 [Yahoo! Finance]

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}